Combined therapy with statins and fibrates for people with dyslipidaemia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  Ciapponi, Agustín ^a   Garcia Marti, Sebastian ^a   Rey Ares, Lucila ^a   Colantonio, Lisandro Damián ^b  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTED ARTICLE;

EID: 84997065480     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006969.pub2     Document Type: Article

References (35)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. [MEDLINE: PMID: 7968073]
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22. [MEDLINE: PMID: 9613910]
3. American Heart Association. Heart disease and Stroke Statistics 2007 Update. http://www.americanheart.org/presenter.jhtml?identifier=3000090 2007:1-43.
4. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. [MEDLINE: PMID: 12686036]
5. Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27. [MEDLINE: PMID: 10880410]
6. Boden W, MD FACC. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia manegement. Current opinion in Cardiology 2003;18:278-285. [MEDLINE: PMID: 12858126]
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The New England Journal of Medicine 1996;335:1001-9. [MEDLINE: PMID: 8801446]
8. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
9. (No Authors listed). Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10. [MEDLINE: PMID: 11289345]
10. Davidson, M, MD. Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy. American Journal of Cardiology 2005;96 (suppl):3K-13K. [MEDLINE: PMID: 16291008]
11. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal 2003;24(17):1601-10. [0195-668X (Print)]
12. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21 (4):641-648. [MEDLINE: PMID: 9571357]
13. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366 (9500):1849-61. [MEDLINE: PMID: 16310551]
14. Frick MH, Elo MO, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 1987;317:1237-45. [MEDLINE: PMID: 3313041]
15. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39. [1524-4539 (Electronic)]
16. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21:1539-58.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
18. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. [MEDLINE: PMID: 12114036]
20. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
21. Law M. MD, Rudnicka A. PhD. Statins safety: A Systematic Review. American Journal of Cardiology 2006;97 (suppl):52C-60C. [MEDLINE: PMID: 16581329]
22. Liberati A, Altman DG, TetzlaffJ, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA Statement for Reporting Systematic and Meta-Analyses of Studies That Evaluate Interventions: Explanation and Elaboration. PLoS Med 1999;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
23. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The New England Journal of Medicine 1998;339:1349-57. [MEDLINE: PMID: 9841303]
24. Mackay, J. Mensah, G. The Atlas of Heart Disease and Stroke. World Health Organization, 2004. [ISBN-13 9789241562768]
25. Expert Panel on Detection, Evaluation, and Treatment. on Detection, Evaluation, and Treatment. and. National Cholesterol Education Program. High Blood Cholesterol in Adults. National Institute of Health, National Heart, Lung, and Blood Institute. 1988:1-87.
26. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; Vol. 89, issue 1333-1445. [MEDLINE: PMID: 8124825]
27. Expert Panel on detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of The National Cholesterol Education Program. Expert Panel on detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart Lung and Blood Institute 2002:1-284. [02-5215]
28. National Institute of Clinical Excellence. Statins for the Prevention of Cardiovascular Events. Technology Appraisal 94. www.nice.org.uk/TA094 2006:1-45.
29. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002;360:1623-30. [MEDLINE: PMID: 12457784]
30. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Veterans Affairs High- Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New England Journal of Medicine 1999;341:410-418. [MEDLINE: PMID: 10438259]
31. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
32. Szapary P, Rader D. The triglyceride-high-density lipoprotein axis: An important target of therapy. American Heart Journal 2004;148:211-221. [MEDLINE: PMID: 15308990]
33. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischemic heart disease using clofibrate: Report from the Committee of Principal Investigators. British Heart Journal 1978;40:1069-118. [MEDLINE: PMID: 361054]
34. Anonymous. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. The Lancet 1984;2 (8403):600-604. [MEDLINE: PMID: 6147641]
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine 1995;333:1301-07. [MEDLINE: PMID: 7566020]